Salvanou, E.-A.; Kolokithas-Ntoukas, A.; Prokopiou, D.; Theodosiou, M.; Efthimiadou, E.; Koźmiński, P.; Xanthopoulos, S.; Avgoustakis, K.; Bouziotis, P.
177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer. Molecules 2024, 29, 1030.
https://doi.org/10.3390/molecules29051030
AMA Style
Salvanou E-A, Kolokithas-Ntoukas A, Prokopiou D, Theodosiou M, Efthimiadou E, Koźmiński P, Xanthopoulos S, Avgoustakis K, Bouziotis P.
177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer. Molecules. 2024; 29(5):1030.
https://doi.org/10.3390/molecules29051030
Chicago/Turabian Style
Salvanou, Evangelia-Alexandra, Argiris Kolokithas-Ntoukas, Danai Prokopiou, Maria Theodosiou, Eleni Efthimiadou, Przemysław Koźmiński, Stavros Xanthopoulos, Konstantinos Avgoustakis, and Penelope Bouziotis.
2024. "177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer" Molecules 29, no. 5: 1030.
https://doi.org/10.3390/molecules29051030
APA Style
Salvanou, E.-A., Kolokithas-Ntoukas, A., Prokopiou, D., Theodosiou, M., Efthimiadou, E., Koźmiński, P., Xanthopoulos, S., Avgoustakis, K., & Bouziotis, P.
(2024). 177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer. Molecules, 29(5), 1030.
https://doi.org/10.3390/molecules29051030
